HTTIF (HighTide Therapeutics) ROCE %: -56.71% (As of Dec. 2025)


HTTIF HighTide Therapeutics Inc HTTIF
14 GF Score
Price $0.35
! 3 Warning Signs
View Full Analysis

What is HighTide Therapeutics ROCE %?

HighTide Therapeutics HTTIF 14 ROCE % is -56.71% as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. HighTide Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2025 was -56.71%.

HighTide Therapeutics  (OTCPK:HTTIF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

HighTide Therapeutics ROCE % Related Terms

HighTide Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for HighTide Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HighTide Therapeutics ROCE % Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
-28.87 -106.27 -782.00 -64.44 -51.67

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only -134.06 -64.90 -66.75 -54.44 -56.71
HTTIF
14GF Score
HighTide Therapeutics Inc HTTIF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HighTide Therapeutics ROCE % Calculation

HighTide Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-32.587/( ( (76.906 - 15.101) + (78.28 - 13.955) )/ 2 )
=-32.587/( (61.805+64.325)/ 2 )
=-32.587/63.065
=-51.67 %

HighTide Therapeutics's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-33.292/( ( (73.6 - 20.519) + (78.28 - 13.955) )/ 2 )
=-33.292/( ( 53.081 + 64.325 )/ 2 )
=-33.292/58.703
=-56.71 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -56.71% mean?
HighTide Therapeutics (HTTIF) has a ROCE % of -56.71% as of Dec. 2025.
Is HighTide Therapeutics' ROCE % too high?
HighTide Therapeutics' current ROCE % is -56.71%. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' ROCE % compare to VRTX and REGN?
HighTide Therapeutics' ROCE % of -56.71% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. HighTide Therapeutics's current ROCE % is -56.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current ROCE % of -56.71%. The current ROCE % is -56.71%. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current ROCE % is -56.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HighTide Therapeutics Business Description

Other Exchanges 02511:Hong Kong
Address Fubao Street, 9th to 10th Floor, Building D, Shenfang Park, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score

Get the complete analysis for HTTIF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price